Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden. Academic Article

abstract

• We characterized clinically occurring and novel mutations in the subunit of RNA polymerase in Clostridium difficile (CdRpoB), conferring rifamycin (including rifaximin) resistance. The Arg505Lys substitution did not impose an in vitro fitness cost, which may be one reason for its dominance among rifamycin-resistant clinical isolates. These observations were supported through the structural modeling of CdRpoB. In general, most mutations lacked in vitro fitness costs, suggesting that rifamycin resistance may in some cases persist in the clinic.

authors

• Hurdle, Julian

published proceedings

• Antimicrob Agents Chemother

altmetric score

• 14.45

author list (cited authors)

• Dang, U. T., Zamora, I., Hevener, K. E., Adhikari, S., Wu, X., & Hurdle, J. G.

citation count

• 13

complete list of authors

• Dang, Uyen T||Zamora, Idalia||Hevener, Kirk E||Adhikari, Sudip||Wu, Xiaoqian||Hurdle, Julian G

publication date

• September 2016

publisher

• American Society for Microbiology  Publisher

published in

• Antimicrobial Agents and Chemotherapy  Journal

keywords

• Anti-Bacterial Agents
• Clostridioides Difficile
• DNA-Directed RNA Polymerases
• Drug Resistance, Bacterial
• Enterocolitis, Pseudomembranous
• Humans
• Microbial Sensitivity Tests
• Mutation
• Rifamycins
• Rifaximin

PubMed Central ID

• 27381389

Digital Object Identifier (DOI)

• 10.1128/AAC.01137-16

URI

• https://hdl.handle.net/1969.1/181890

start page

• 5604

end page

• 5607

volume

• 60

issue

• 9

URL

• http://dx.doi.org/10.1128/aac.01137-16